Glycoscience fuels a new breed of cancer immunotherapy

Start-ups like Palleon and NextCure look to broaden the benefits of immuno-oncology with drugs that target a protein family called Siglecs and their glycan ligands

Source: Chemical and Engineering News - July 20, 2019 Category: Chemistry Authors: Esther Landhuis, special to C & EN Source Type: research